BioWorld Asia

April 17, 2002

Medivir, Roche In $42M Pact For Preclinical HIV Compound

Swedish biotechnology firm Medivir AB unveiled Monday its biggest drug development deal to date a licensing agreement worth up to US$42 million with F. Hoffmann-La Roche Ltd. for Medivir’s candidate HIV treatment, MV026048. (BioWorld International) Read More

Abbott Seeks Approvals For CAT’s Monoclonal Antibody

Gene Expression Variations May Account For Chimp-Human Divide

Hybrigenics Raises $14.8M In Third Funding Round

Micromet, Enzon Collaborate On Single-Chain Antibodies

Other News To Note

Paradigm, Genmab Collaborate In Therapeutic Antibodies Deal

Start-Up CareX Raises $5.2M In Initial Funding Round

Epidauros, Pharmacia Broaden Pharmacogenetics Collaboration

Two Peptech Directors, Chairman Resign After Only Three Months

Prana Releases Positive News In Phase II of Alzheimer’s Drug

EU Advisory Group Calls For Changes In Biotech Proposals

Pharmexa Reveals GSK Option On Breast Cancer Vaccine

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...